The Vanquish procedure may be a compelling option at East Valley Urology Center of Arizona (EVU) because EVU was among the first Arizona practices to offer it commercially for targeted prostate-tissue ablation. In March 2026, EVU’s Dr. Rahul Mehan performed Arizona’s first routine commercial Vanquish procedures outside a formal clinical trial, at Verve Surgery Center in Mesa.
With office locations in Mesa, Queens Creek, Scottsdale and Globe patients now have multiple local locations to have their evaluation completed.
What Vanquish is
Vanquish is a minimally invasive, transurethral procedure: the physician passes the device through the urethra rather than making surgical incisions. It uses image guidance—typically pre-procedure MRI combined with live ultrasound and electromagnetic tracking—to position a needle-shaped catheter in selected prostate tissue. Short bursts of sterile water vapor transfer thermal energy and ablate, or destroy, the intended tissue zone and a planned margin.
It is designed to target lesions throughout the prostate while respecting natural tissue boundaries. The procedure is generally outpatient and typically performed under general anesthesia, so eligible patients often return home the same day.
Why EVU may be advantageous
Important limitations
The strongest reason to be careful with marketing language is that Vanquish is new. The FDA clearance referenced for the system is for thermal ablation of targeted prostate tissue via a transurethral approach; it does not mean the FDA evaluated Vanquish as a cure for prostate cancer or established long-term prostate-cancer outcomes.
Therefore, patients should not interpret “minimally invasive” as “risk-free” or “best proven.” Research and long-term comparative data are more established for some other prostate-cancer approaches, including active surveillance for eligible low-risk disease, prostatectomy, radiation, and certain established focal-therapy pathways. The appropriate comparison needs to be personalized.
Questions to ask EVU
Before deciding whether Vanquish is the better option, a patient should ask Dr. Mehan or member doctors of the EVU Center team:
- Am I a candidate based on my MRI, biopsy grade/group, PSA, cancer location, and stage?
- Is my disease suitable for focal/targeted ablation, or would whole-gland treatment or active surveillance be safer?
- How much prostate tissue and what treatment margin will be ablated?
- What are EVU’s current outcomes for cancer control, urinary continence, erections, infection, retention, catheter duration, and retreatment?
- How will success be monitored—PSA testing, repeat MRI, repeat biopsy, and at what intervals?
- What are the alternatives in my case, including surgery, radiation, HIFU, surveillance, or clinical trials?
- Is Vanquish covered by my insurer, and what expenses could remain out of pocket?
Bottom line
At EVU, Vanquish’s main differentiator is a combination of targeted, incision-free outpatient treatment and early Arizona clinical availability through Dr. Rahul Mehan’s team. It may be an attractive option for a carefully selected patient with localized prostate cancer who wants to explore focal treatment, but it should be positioned as an emerging, individualized option—not a universal replacement for surgery, radiation, surveillance, or other prostate-cancer therapies.
